Inflammation in Peritoneal Dialysis Patients: Effect of Obesity

Withdrawn before enrolling

Conditions studied: End-Stage Renal Disease, Renal Disease, End-Stage, Renal Failure, End-Stage, Obesity

In brief

Our study addresses the following research question: What is the role of obesity in modulating inflammation and innate immune function, as well as the overall responsiveness of innate immune cells (such as macrophages, neutrophils, and other peripheral leukocytes) in patients undergoing peritoneal dialysis? The investigators hypothesize that obesity will lead to increased inflammation in patients undergoing peritoneal dialysis.

Key facts

Study ID

NCT01691196

Run by

University of Illinois at Chicago

People needed

0

Starts

2012-09-01

Expected to finish

2017-09-01

Last updated by the study team

2019-10-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• > 18 years; and
• peritoneal dialysis (PD) > 6 months.

You may not qualify if…

• infectious episode within 4 weeks; and
• using immunosuppressive drugs

Where it is running

• University of Illinois at Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.